Max Wolff
@trpwolff.bsky.social
Psychologist and clinician-researcher; psychotherapy integration, psychedelic-augmented psychotherapy
Research associate at Central Institute of Mental Health, Mannheim & Charité Berlin
Research associate at Central Institute of Mental Health, Mannheim & Charité Berlin
Reposted by Max Wolff
Is the psychedelic experience a pharmacodynamic biomarker? Or do psychotherapeutic processes matter? Comment with @trpwolff.bsky.social on the recent Goodwin et al. (2025) paper now available online in the Journal of Affective Disorders: www.sciencedirect.com/science/arti...
Pharmacodynamic biomarker or psychotherapeutic process? Comment on “the role of the psychedelic experience in psilocybin treatment for treatment-resistant depression”
www.sciencedirect.com
November 10, 2025 at 7:00 PM
Is the psychedelic experience a pharmacodynamic biomarker? Or do psychotherapeutic processes matter? Comment with @trpwolff.bsky.social on the recent Goodwin et al. (2025) paper now available online in the Journal of Affective Disorders: www.sciencedirect.com/science/arti...
Reposted by Max Wolff
Postdoctoral Fellowship Opportunity
We are looking for excellent MD Psychiatrist applicants to work & train at the CPCR at Johns Hopkins
@jhpsychedelics.bsky.social, the largest and most comprehensive psychedelic research program in the world.
Email Dr. Sandeep Nayak smn@jhmi.edu
We are looking for excellent MD Psychiatrist applicants to work & train at the CPCR at Johns Hopkins
@jhpsychedelics.bsky.social, the largest and most comprehensive psychedelic research program in the world.
Email Dr. Sandeep Nayak smn@jhmi.edu
October 30, 2025 at 7:53 PM
Postdoctoral Fellowship Opportunity
We are looking for excellent MD Psychiatrist applicants to work & train at the CPCR at Johns Hopkins
@jhpsychedelics.bsky.social, the largest and most comprehensive psychedelic research program in the world.
Email Dr. Sandeep Nayak smn@jhmi.edu
We are looking for excellent MD Psychiatrist applicants to work & train at the CPCR at Johns Hopkins
@jhpsychedelics.bsky.social, the largest and most comprehensive psychedelic research program in the world.
Email Dr. Sandeep Nayak smn@jhmi.edu
Reposted by Max Wolff
Finally got around to reading this great paper. A really insightful argument for treating psychedelic-assisted therapy as psychotherapy!
New long-read theory paper in Psychological Review:
Im short, we propose that effective psychedelic therapy employs the uniquely context-dependent effects of psychedelic drugs to engage & augment the same psychological change processes that underlie all effective psychotherapies.
Full text below ⬇️
Im short, we propose that effective psychedelic therapy employs the uniquely context-dependent effects of psychedelic drugs to engage & augment the same psychological change processes that underlie all effective psychotherapies.
Full text below ⬇️
October 24, 2025 at 1:43 PM
Finally got around to reading this great paper. A really insightful argument for treating psychedelic-assisted therapy as psychotherapy!
To those who dismiss psychodynamic therapy, and perhaps especially to those who dismiss anything except psychodynamic therapy, this article comes highly recommended:
psycnet.apa.org/doiLanding?d...
psycnet.apa.org/doiLanding?d...
October 18, 2025 at 6:08 AM
To those who dismiss psychodynamic therapy, and perhaps especially to those who dismiss anything except psychodynamic therapy, this article comes highly recommended:
psycnet.apa.org/doiLanding?d...
psycnet.apa.org/doiLanding?d...
Reposted by Max Wolff
I've been saying that since I was 18, as I exited a Jimi Hendrix concert in Kansas City
October 11, 2025 at 7:14 AM
I've been saying that since I was 18, as I exited a Jimi Hendrix concert in Kansas City
New long-read theory paper in Psychological Review:
Im short, we propose that effective psychedelic therapy employs the uniquely context-dependent effects of psychedelic drugs to engage & augment the same psychological change processes that underlie all effective psychotherapies.
Full text below ⬇️
Im short, we propose that effective psychedelic therapy employs the uniquely context-dependent effects of psychedelic drugs to engage & augment the same psychological change processes that underlie all effective psychotherapies.
Full text below ⬇️
October 10, 2025 at 8:22 PM
New long-read theory paper in Psychological Review:
Im short, we propose that effective psychedelic therapy employs the uniquely context-dependent effects of psychedelic drugs to engage & augment the same psychological change processes that underlie all effective psychotherapies.
Full text below ⬇️
Im short, we propose that effective psychedelic therapy employs the uniquely context-dependent effects of psychedelic drugs to engage & augment the same psychological change processes that underlie all effective psychotherapies.
Full text below ⬇️
Classical randomized controlled trials (RCTs) can't capture the complexity of psychedelic therapy.
In this new paper led by @sdmuthu.bsky.social and @tehseennoorani.bsky.social, we argue for pragmatic trials designs that accommodate this complexity and better align with real-world clinical practice.
In this new paper led by @sdmuthu.bsky.social and @tehseennoorani.bsky.social, we argue for pragmatic trials designs that accommodate this complexity and better align with real-world clinical practice.
October 9, 2025 at 9:01 AM
Classical randomized controlled trials (RCTs) can't capture the complexity of psychedelic therapy.
In this new paper led by @sdmuthu.bsky.social and @tehseennoorani.bsky.social, we argue for pragmatic trials designs that accommodate this complexity and better align with real-world clinical practice.
In this new paper led by @sdmuthu.bsky.social and @tehseennoorani.bsky.social, we argue for pragmatic trials designs that accommodate this complexity and better align with real-world clinical practice.
Reposted by Max Wolff
New paper out with @tehseennoorani.bsky.social @maxwolff.bsky.social and orhers, showing that the UK Medical Research Council's framework for complex interventions offer an important way foward for the field of #psychedelics:
journals.sagepub.com/doi/epub/10....
journals.sagepub.com/doi/epub/10....
Psychedelic-assisted therapy as a complex intervention: implications for clinical trial design
journals.sagepub.com
October 8, 2025 at 1:41 PM
New paper out with @tehseennoorani.bsky.social @maxwolff.bsky.social and orhers, showing that the UK Medical Research Council's framework for complex interventions offer an important way foward for the field of #psychedelics:
journals.sagepub.com/doi/epub/10....
journals.sagepub.com/doi/epub/10....
Has the time come to stop using "control groups" in trials of psychological interventions? — asks Pim Cuijpers.
This discussion concerns psychedelic therapy, which is a (pharmacologically catalyzed) psychological intervention, just as well as any other form of psychotherapy.
Link below.
This discussion concerns psychedelic therapy, which is a (pharmacologically catalyzed) psychological intervention, just as well as any other form of psychotherapy.
Link below.
October 1, 2025 at 3:20 AM
Has the time come to stop using "control groups" in trials of psychological interventions? — asks Pim Cuijpers.
This discussion concerns psychedelic therapy, which is a (pharmacologically catalyzed) psychological intervention, just as well as any other form of psychotherapy.
Link below.
This discussion concerns psychedelic therapy, which is a (pharmacologically catalyzed) psychological intervention, just as well as any other form of psychotherapy.
Link below.
From our recent article "Key competencies for psychedelic treatment in real-world mental health care settings"
Full-text link below.
Full-text link below.
September 29, 2025 at 8:15 AM
From our recent article "Key competencies for psychedelic treatment in real-world mental health care settings"
Full-text link below.
Full-text link below.
Reposted by Max Wolff
Recovering memories under MDMA or psychedelics and the impact of The Tell, a few scattered thoughts and observations: kangaslampi.net/the-tell-and...
The Tell and recovered memories under MDMA and psychedelics – Samuli Kangaslampi
kangaslampi.net
September 25, 2025 at 10:15 AM
Recovering memories under MDMA or psychedelics and the impact of The Tell, a few scattered thoughts and observations: kangaslampi.net/the-tell-and...
Our new paper "Key competencies for psychedelic treatment in real-world mental health care settings" has just been published in General Hospital Psychiatry.
Full-text link below.
Full-text link below.
September 21, 2025 at 5:48 AM
Our new paper "Key competencies for psychedelic treatment in real-world mental health care settings" has just been published in General Hospital Psychiatry.
Full-text link below.
Full-text link below.
Reposted by Max Wolff
My article "Experiments in medicalization" on the Swiss and Australian efforts to enable psychedelic therapies outside of clinical trials but short of market approval has just come out in BioSocieties: www.nicolaslanglitz.de/ewExternalFi...
www.nicolaslanglitz.de
September 6, 2025 at 3:07 PM
My article "Experiments in medicalization" on the Swiss and Australian efforts to enable psychedelic therapies outside of clinical trials but short of market approval has just come out in BioSocieties: www.nicolaslanglitz.de/ewExternalFi...
Bluesky now platform of choice for science community - except for the psychedelic science community, which seems to have chosen Linkedin.
What does this say about psychedelic science?
What does this say about psychedelic science?
Bluesky now platform of choice for science community - Ars Technica | Media coverage of our new paper
Bluesky now platform of choice for science community
It’s not just you. Survey says: “Twitter sucks now and all the cool kids are moving to Bluesky”…
arstechnica.com
August 28, 2025 at 5:23 AM
Bluesky now platform of choice for science community - except for the psychedelic science community, which seems to have chosen Linkedin.
What does this say about psychedelic science?
What does this say about psychedelic science?
Reposted by Max Wolff
BREAKING: German regulators have green-lit the EU's first psilocybin compassionate access program.
Unlike other countries’ pre-approval pathways, Germany’s does not require case-by-case regulatory approval and may see insurers cover costs.
Details: psychedelicalpha.com/news/germany...
Unlike other countries’ pre-approval pathways, Germany’s does not require case-by-case regulatory approval and may see insurers cover costs.
Details: psychedelicalpha.com/news/germany...
Germany Establishes EU’s First Psilocybin Compassionate Access Program - Psychedelic Alpha
Germany has become the first EU country to allow legal access to psilocybin under a compassionate use program for treatment-resistant depression. Unlike other countries’ pre-approval pathways, Germany...
psychedelicalpha.com
July 31, 2025 at 8:03 AM
BREAKING: German regulators have green-lit the EU's first psilocybin compassionate access program.
Unlike other countries’ pre-approval pathways, Germany’s does not require case-by-case regulatory approval and may see insurers cover costs.
Details: psychedelicalpha.com/news/germany...
Unlike other countries’ pre-approval pathways, Germany’s does not require case-by-case regulatory approval and may see insurers cover costs.
Details: psychedelicalpha.com/news/germany...
Our recent article "Reframing psychedelic regulation: Tools, not treatments" is discussed on the SPACE blog (in Portuguese): space.com.pt/blogue/regul...
Regulamentar Psicadélicos como Ferramentas, Não como Tratamentos | SPACE Portugal — Sociedade Portuguesa de Aplicação Clínica de Enteógenos
O artigo de Wolff et al. (2025), "Reframing psychedelic regulation: Tools, not treatments", constitui uma contribuição oportuna e...
space.com.pt
July 20, 2025 at 12:14 PM
Our recent article "Reframing psychedelic regulation: Tools, not treatments" is discussed on the SPACE blog (in Portuguese): space.com.pt/blogue/regul...
Reposted by Max Wolff
Big news for psychedelic research in Europe:
The new €4.3M INTEGRATE project will train 16 PhDs across Europe. Funded by Marie Skłodowska-Curie Actions, it marks a major step forward. PAREA is proud to support by hosting secondments.
More here: parea.eu/parea-news/i...
The new €4.3M INTEGRATE project will train 16 PhDs across Europe. Funded by Marie Skłodowska-Curie Actions, it marks a major step forward. PAREA is proud to support by hosting secondments.
More here: parea.eu/parea-news/i...
Europe Invests in the Future of Psychedelic Science: INTEGRATE Doctoral Network Launches with €4.3 Million in Funding — PAREA
A second major EU-funded project in psychedelic science, following PsyPal, will start in the coming months. INTEGRATE will be a doctoral training network supported by €4.3 million in EU funding throug...
parea.eu
July 15, 2025 at 3:03 PM
Big news for psychedelic research in Europe:
The new €4.3M INTEGRATE project will train 16 PhDs across Europe. Funded by Marie Skłodowska-Curie Actions, it marks a major step forward. PAREA is proud to support by hosting secondments.
More here: parea.eu/parea-news/i...
The new €4.3M INTEGRATE project will train 16 PhDs across Europe. Funded by Marie Skłodowska-Curie Actions, it marks a major step forward. PAREA is proud to support by hosting secondments.
More here: parea.eu/parea-news/i...
Small feasibility study testing MDMA-assisted psychotherapy for major depression, unsurprisingly with promising results, from Norway.
www.cambridge.org/core/journal...
www.cambridge.org/core/journal...
July 11, 2025 at 1:23 PM
Small feasibility study testing MDMA-assisted psychotherapy for major depression, unsurprisingly with promising results, from Norway.
www.cambridge.org/core/journal...
www.cambridge.org/core/journal...
Doing psychedelic research with Spanish-speaking populations & interested in avoidance/acceptance?
There is now a culturally decentered Spanish APEQ version designed to work equally well across the Spanish-speaking world:
www.sciencedirect.com/science/arti...
There is now a culturally decentered Spanish APEQ version designed to work equally well across the Spanish-speaking world:
www.sciencedirect.com/science/arti...
July 9, 2025 at 9:28 PM
Doing psychedelic research with Spanish-speaking populations & interested in avoidance/acceptance?
There is now a culturally decentered Spanish APEQ version designed to work equally well across the Spanish-speaking world:
www.sciencedirect.com/science/arti...
There is now a culturally decentered Spanish APEQ version designed to work equally well across the Spanish-speaking world:
www.sciencedirect.com/science/arti...
Reposted by Max Wolff
New Viewpoint: Countries allowing assisted suicide should offer candidates psychedelics and support to change their minds. If we truly value life, shouldn't we explore every therapeutic option - even controversial ones - before accepting that suffering is untreatable?
ja.ma/4l2gdls
ja.ma/4l2gdls
July 1, 2025 at 9:25 AM
New Viewpoint: Countries allowing assisted suicide should offer candidates psychedelics and support to change their minds. If we truly value life, shouldn't we explore every therapeutic option - even controversial ones - before accepting that suffering is untreatable?
ja.ma/4l2gdls
ja.ma/4l2gdls
This seems relevant to psychedelic research, where expectancy is still often viewed only as a baseline variable. We should also consider its dynamic changes, how (psychedelic & other) treatment experiences influence them, and their impact on outcomes.
@psybalazs.bsky.social
@theborislab.bsky.social
@psybalazs.bsky.social
@theborislab.bsky.social
In psychotherapy, treatment expectations matter. But even more powerful? ➡️ How they change over time. Our new paper shows that updating expectations during psychotherapy for MDD predicts depression outcomes. 🔗 www.tandfonline.com/eprint/WRBWU...
#depression #psychotherapy #beliefupdating
#depression #psychotherapy #beliefupdating
Dynamic expectancies: The independent role of within-person change in outcome expectancy in predicting overall treatment outcomes in psychotherapy for depression
Dynamic changes in patients’ outcome expectancy have been increasingly recognized as important for psychotherapy success. However, whether expectancy change predicts treatment outcomes independentl...
www.tandfonline.com
June 30, 2025 at 4:30 AM
This seems relevant to psychedelic research, where expectancy is still often viewed only as a baseline variable. We should also consider its dynamic changes, how (psychedelic & other) treatment experiences influence them, and their impact on outcomes.
@psybalazs.bsky.social
@theborislab.bsky.social
@psybalazs.bsky.social
@theborislab.bsky.social
Reposted by Max Wolff
Enjoyed this recent paper about considering psychedelics as tools to accelerate psychotherapy vs interventions in and of themselves. doi.org/10.1177/2050... #psychedelicscience
Sage Journals: Discover world-class research
Subscription and open access journals from Sage, the world's leading independent academic publisher.
doi.org
June 26, 2025 at 8:33 PM
Enjoyed this recent paper about considering psychedelics as tools to accelerate psychotherapy vs interventions in and of themselves. doi.org/10.1177/2050... #psychedelicscience
Reposted by Max Wolff
Please join me next Wed at Einstein Center for Neurosciences Berlin 🇩🇪 for an in depth discussion about evidence and mechanisms in psychedelic therapies.
I'll finish with a brief spoiler about a new project coming on, in my new role at ULisbon 🇵🇹 💫
I'll finish with a brief spoiler about a new project coming on, in my new role at ULisbon 🇵🇹 💫
June 25, 2025 at 3:21 PM
Please join me next Wed at Einstein Center for Neurosciences Berlin 🇩🇪 for an in depth discussion about evidence and mechanisms in psychedelic therapies.
I'll finish with a brief spoiler about a new project coming on, in my new role at ULisbon 🇵🇹 💫
I'll finish with a brief spoiler about a new project coming on, in my new role at ULisbon 🇵🇹 💫
Reposted by Max Wolff
Die Universität Würzburg bietet jetzt zum ersten Mal ein Zertifikatsprogramm zum Thema "Machtmissbrauch erkennen und verhindern" (MEV) an. Die Teilnahme ist kostenlos.
Im Verlauf eines Jahres werden Wissens- und Handlungskompetenzen in diesem Bereich vermittelt (jeweils 1 Modul).
Im Verlauf eines Jahres werden Wissens- und Handlungskompetenzen in diesem Bereich vermittelt (jeweils 1 Modul).
June 21, 2025 at 11:10 AM
Die Universität Würzburg bietet jetzt zum ersten Mal ein Zertifikatsprogramm zum Thema "Machtmissbrauch erkennen und verhindern" (MEV) an. Die Teilnahme ist kostenlos.
Im Verlauf eines Jahres werden Wissens- und Handlungskompetenzen in diesem Bereich vermittelt (jeweils 1 Modul).
Im Verlauf eines Jahres werden Wissens- und Handlungskompetenzen in diesem Bereich vermittelt (jeweils 1 Modul).
Reposted by Max Wolff
A promising approach
Glad to see this paper out finally. Well done @trpwolff.bsky.social for driving it!
I think this idea has potential for significant impact in psychedelic drug development.
/1 🧵 👇
📄 doi.org/10.1177/2050...
I think this idea has potential for significant impact in psychedelic drug development.
/1 🧵 👇
📄 doi.org/10.1177/2050...
June 16, 2025 at 11:01 PM
A promising approach